Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction of adalimumab in overtreated psoriasis patients
2019-001918-42Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in plaque psoriasis (2 arms), sponsored by Ghent University Hospital. Primary endpoints: Clinical remission at 1 year and Relapse requiring dose escalation. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2019-001918-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001918-42.